Glycine Completed Phase 2 Trials for Nicotine Dependence Prevention

IndicationsStatusPurposePhase
CompletedPrevention2
clinicaltrials.gov IdentifierTitleDrugs
NCT00218465Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking